Los Angeles Capital Management LLC Has $398,000 Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

Los Angeles Capital Management LLC lessened its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 9.6% in the third quarter, HoldingsChannel.com reports. The firm owned 95,360 shares of the company’s stock after selling 10,113 shares during the quarter. Los Angeles Capital Management LLC’s holdings in MeiraGTx were worth $398,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Privium Fund Management B.V. grew its position in shares of MeiraGTx by 4.9% during the 3rd quarter. Privium Fund Management B.V. now owns 213,960 shares of the company’s stock worth $892,000 after buying an additional 10,000 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of MeiraGTx by 97.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,886 shares of the company’s stock worth $62,000 after buying an additional 7,330 shares during the period. SG Americas Securities LLC acquired a new stake in shares of MeiraGTx during the 3rd quarter worth approximately $82,000. SkyView Investment Advisors LLC acquired a new stake in shares of MeiraGTx during the 2nd quarter worth approximately $126,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of MeiraGTx by 19.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company’s stock worth $75,000 after buying an additional 2,839 shares during the period. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Price Performance

Shares of MGTX opened at $6.48 on Monday. MeiraGTx Holdings plc has a 12-month low of $3.85 and a 12-month high of $7.60. The business’s fifty day moving average is $5.13 and its 200 day moving average is $4.79. The company has a quick ratio of 2.36, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The stock has a market cap of $506.41 million, a P/E ratio of -5.36 and a beta of 1.24.

Analysts Set New Price Targets

Several brokerages have recently commented on MGTX. Royal Bank of Canada raised their price objective on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of MeiraGTx in a research report on Wednesday, July 31st.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.